Robert James Wills - Net Worth and Insider Trading
Robert James Wills Net Worth
The estimated net worth of Robert James Wills is at least $1 Million dollars as of 2024-12-27. Robert James Wills is the Director of CymaBay Therapeutics Inc and owns about 30,000 shares of CymaBay Therapeutics Inc (CBAY) stock worth over $974,400. Robert James Wills is the Director of Milestone Pharmaceuticals Inc and owns about 15,000 shares of Milestone Pharmaceuticals Inc (MIST) stock worth over $29,700. Robert James Wills is also the Director of Oncternal Therapeutics Inc and owns about 10,000 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $5,266. Details can be seen in Robert James Wills's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Robert James Wills has not made any transactions after 2024-04-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Robert James Wills
Robert James Wills Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Robert James Wills owns 3 companies in total, including Milestone Pharmaceuticals Inc (MIST) , Oncternal Therapeutics Inc (ONCT) , and CymaBay Therapeutics Inc (CBAY) .
Click here to see the complete history of Robert James Wills’s form 4 insider trades.
Insider Ownership Summary of Robert James Wills
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MIST | Milestone Pharmaceuticals Inc | 2022-10-19 | director |
| ONCT | Oncternal Therapeutics Inc | 2024-04-08 | director & Executive Chairman |
| CBAY | CymaBay Therapeutics Inc | 2017-08-01 | director |
Robert James Wills Latest Holdings Summary
Robert James Wills currently owns a total of 3 stocks. Among these stocks, Robert James Wills owns 30,000 shares of CymaBay Therapeutics Inc (CBAY) as of August 1, 2017, with a value of $974,400 and a weighting of 96.54%. Robert James Wills owns 15,000 shares of Milestone Pharmaceuticals Inc (MIST) as of October 19, 2022, with a value of $29,700 and a weighting of 2.94%. Robert James Wills also owns 10,000 shares of Oncternal Therapeutics Inc (ONCT) as of April 8, 2024, with a value of $5,266 and a weighting of 0.52%.
Latest Holdings of Robert James Wills
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CBAY | CymaBay Therapeutics Inc | 2017-08-01 | 30,000 | 32.48 | 974,400 |
| MIST | Milestone Pharmaceuticals Inc | 2022-10-19 | 15,000 | 1.98 | 29,700 |
| ONCT | Oncternal Therapeutics Inc | 2024-04-08 | 10,000 | 0.53 | 5,266 |
Holding Weightings of Robert James Wills
Robert James Wills Form 4 Trading Tracker
According to the SEC Form 4 filings, Robert James Wills has made a total of 0 transactions in CymaBay Therapeutics Inc (CBAY) over the past 5 years. The most-recent trade in CymaBay Therapeutics Inc is the acquisition of 5,000 shares on August 1, 2017, which cost Robert James Wills around $34,200.
According to the SEC Form 4 filings, Robert James Wills has made a total of 1 transactions in Milestone Pharmaceuticals Inc (MIST) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Milestone Pharmaceuticals Inc is the acquisition of 15,000 shares on October 19, 2022, which cost Robert James Wills around $73,950.
According to the SEC Form 4 filings, Robert James Wills has made a total of 3 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Oncternal Therapeutics Inc is the acquisition of 3,086 shares on April 8, 2024, which cost Robert James Wills around $27,651.
Insider Trading History of Robert James Wills
- 1
Robert James Wills Trading Performance
GuruFocus tracks the stock performance after each of Robert James Wills's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Robert James Wills is -10.9%. GuruFocus also compares Robert James Wills's trading performance to market benchmark return within the same time period. The performance of stocks bought by Robert James Wills within 3 months outperforms 4 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Robert James Wills's insider trading performs compared to the benchmark.
Performance of Robert James Wills
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 6.32 | | | | | |
| Relative Return to S&P 500(%) | 5.49 | | | | | |
Robert James Wills Ownership Network
Robert James Wills Owned Company Details
What does Milestone Pharmaceuticals Inc do?
Who are the key executives at Milestone Pharmaceuticals Inc?
Robert James Wills is the director of Milestone Pharmaceuticals Inc. Other key executives at Milestone Pharmaceuticals Inc include Chief Medical Officer David Bharucha , 10 percent owner Roderick Wong , and 10 percent owner Rtw Investments, Lp .
Milestone Pharmaceuticals Inc (MIST) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Milestone Pharmaceuticals Inc (MIST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Milestone Pharmaceuticals Inc (MIST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Milestone Pharmaceuticals Inc (MIST)'s detailed insider trading history can be found in Insider Trading Tracker table.
Milestone Pharmaceuticals Inc Insider Transactions
Robert James Wills Mailing Address
Above is the net worth, insider trading, and ownership report for Robert James Wills. You might contact Robert James Wills via mailing address: 175 Toyota Plaza, 7th Floor, Memphis Tn 38103.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
